Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Operating Income (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Operating Income readings, the most recent being $634000.0 for Q4 2025.

  • On a quarterly basis, Operating Income rose 692.52% to $634000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$489000.0, a 66.85% increase, with the full-year FY2025 number at -$491000.0, up 66.73% from a year prior.
  • Operating Income hit $634000.0 in Q4 2025 for Arcadia Biosciences, up from -$1.2 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $5.6 million in Q4 2021 to a low of -$5.4 million in Q2 2021.
  • Median Operating Income over the past 5 years was -$1.5 million (2023), compared with a mean of -$1.7 million.
  • Biggest five-year swings in Operating Income: plummeted 318.28% in 2021 and later skyrocketed 692.52% in 2025.
  • Arcadia Biosciences' Operating Income stood at $5.6 million in 2021, then plummeted by 183.33% to -$4.7 million in 2022, then surged by 74.39% to -$1.2 million in 2023, then soared by 91.03% to -$107000.0 in 2024, then skyrocketed by 692.52% to $634000.0 in 2025.
  • The last three reported values for Operating Income were $634000.0 (Q4 2025), -$1.2 million (Q3 2025), and -$501000.0 (Q2 2025) per Business Quant data.